Why the study?
MINOCA is associated with significant mortality, angina burden, and socioeconomic costs, but randomized clinical trials and evidence supporting a standardized diagnostic algorithm and clinical management are lacking.
Answers are grounded in this paper and cite their sources.
This review highlights the potential of a precision medicine approach to improve outcomes and quality of life in patients with MINOCA, as evaluated in the PROMISE trial.
Myocardial infarction with non-obstructive coronary arteries (MINOCA) is a working diagnosis encompassing several pathophysiological mechanisms with specific treatments and different prognoses. Despite the absence of obstructive coronary artery disease, MINOCA has proven to be associated with a significant risk of mortality, angina burden, and socioeconomic costs. However, due to the heterogeneous nature of this clinical condition and the absence of randomized clinical trials, evidence supporting a standardized diagnostic algorithm and the clinical management of these patients is lacking. The PROMISE trial is the first randomized clinical trial evaluating the effectiveness of a precision medicine approach strategy in improving the outcomes and quality of life of patients with MINOCA, offering new insights into personalized treatment strategies. This review article discusses the promise of a precision medicine approach in patients with MINOCA, highlighting the potential innovations and challenges of a personalized medicine strategy in MINOCA.
No takes yet. Share an insight, caveat, or question.
Vecchia et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: